New prospects for autoimmune disease therapy: B cells on deathwatch.
New prospects for autoimmune disease therapy: B cells on deathwatch.
复制标题
自身免疫性疾病治疗的新前景：死亡观察中的 B 细胞。
DOI：
10.1002/art.21525
复制
发表时间：
2006
影响因子：
--
通讯作者：
Tedder,ThomasF
中科院分区：
文献类型：
--
作者：
StClair,EWilliam;Tedder,ThomasF
利妥昔单抗去除B细胞后类风湿关节炎(RA)的体征和症状的改善激发了人们对B细胞在自身免疫性疾病中的作用的兴趣。几十年来，B细胞一直是许多研究人员关注的焦点，他们致力于了解各种免疫介导的疾病，包括RA、Sjögren综合征和系统性红斑狼疮(SLE)。然而，B细胞并没有被普遍认为在系统性硬化症(SSC)的发病机制中发挥关键作用。松下及其同事在本期《关节炎和风湿病》(1)上发表的一项研究呼吁人们注意B细胞在SSC中的潜在关键作用。他们表明，患有这种疾病的患者血清中可溶性BAFF(也被称为B淋巴细胞刺激因子[BLyS；人类基因组科学的商标，马里兰州罗克维尔])水平升高，这是一种有效的B细胞生存因子。Matsushita等人报道的结果增加了BAFF可能促进SSC中致病B细胞存活的可能性，从而有助于疾病的表达。到目前为止，本研究的另一个发现是，SSc B细胞表达BAFF受体(BAFFR)的数量增加，并过度表达BAFF受体。
The improvement seen in the signs and symptoms of rheumatoid arthritis (RA) following B cell depletion with rituximab has fueled interest in the role of B cells in autoimmune disease. For several decades, B cells have been the focus of many investigators working to understand a variety of immune-mediated diseases, including RA, Sjögren’s syndrome, and systemic lupus erythematosus (SLE). B cells, however, have not generally been thought to play a critical role in the mechanisms of systemic sclerosis (SSc). A study by Matsushita and colleagues, in this issue of Arthritis & Rheumatism (1), calls attention to B cells as potential key players in SSc. They show that patients with this disease have elevated serum levels of soluble BAFF (also known as B lymphocyte stimulator [BLyS; trademark of Human Genome Sciences, Rockville, MD]), a potent B cell survival factor.The results reported by Matsushita et al raise the possibility that BAFF may promote the survival of pathogenic B cells in SSc and therefore contribute to disease expression. To this point, an additional finding of this study was that SSc B cells express increased amounts of the BAFF receptor (BAFFR) and overpro-